Turkish Abstract Abstract Article PDF Similar Articles Mail to Author

¹İBÜ, Avrupa Florence Nİghthingale Eğitim ve Araştırma Hast., İstanbul, Yard. Doç. Dr.
²İBÜ, Avrupa Florence Nİghthingale Eğitim ve Araştırma Hast., İstanbul, Asist. Dr.
³İBÜ, Avrupa Florence Nİghthingale Eğitim ve Araştırma Hast., İstanbul, Prof. Dr. Purpose: To describe and report the effect of intravitreal bevacizumab as primary treatment for secondary choroidal neovascularization (CNV) after choroidal rupture due to blunt head trauma. The study included two eyes of two patients who presented with choroidal neovascularization secondary to choroidal rupture due to blunt head trauma. Both patients received single intravitreal injection of 1.25 mg (0.05 ml) bevacizumab (as treatment of CNV) after informed consent was signed. Both patient also underwent fundus fluorescein angiography (FA), optic coherence tomography (OCT) before the bevacizumab injection and then three months after. Visual acuity was measured before and after treatment by ETDRS chart. Patients were reexamined on the first day, and monthly thereafter. After intravitreal injection of bevacizumab, the visual acuity and anatomic responses were observed. Both patients showed regression of their neovascularization three months after injection of bevacizumab. No eyes lost vision during follow- up and both eyes showed improvement. At 3^rd month of treatment, one eye’s vision improved from 20/60 to 20/20, other eye’s visual acuity (VA) improved from 20/50 to 20/30. Central retinal thickness decreased in both eyes. No cataract progression, endophthalmitis or injection-related complications were encountered. Our study shows that intravitreal 1.25 mg bevacizumab can be an effective alternative treatment for choroidal neovascularization (CNV) due to choroidal rupture. Keywords : Blunt head trauma, choroidal rupture, choroidal neovascularization, intravitreal bevacizumab